Log in to your Inderes Free account to see all free content on this page.
Cantargia
3.45 SEK -0.58%1,320 investors are following this company
Cantargia is a pharmaceutical company. Today, there is specialization in the development of antibody drugs used in the treatment of leukemia and other cancers such as lung and pancreatic cancer. The company's objective is to develop, sell and license drug candidates to companies operating in the mentioned work area. The largest operations are in the Nordic market, with headquarters in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CANTA
Daily low / high price
3.32 / 3.494
SEK
Market cap
633.72M SEK
Turnover
897.6K SEK
Volume
264K
Latest videos
Financial calendar
Interim report
21.05.2024
General meeting
23.05.2024
Interim report
28.08.2024
Interim report
15.11.2024
Annual report
21.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Fjärde AP-fonden | 9.9 % | 9.9 % |
Första AP-Fonden | 7.1 % | 7.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Notice of annual general meeting in Cantargia AB (publ)
Cantargia publishes new data on the CAN10 antibody, detailing its interaction with IL1RAP and functional inhibition
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio